4th Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to implementation of FDAAA, BIO priorities (Chairmanship) (no specific bills); HR 2552 - Hepatitis C Epidemic Control Prevention Act of 2007; all provisions; Increased appropriations for CDC/FDA.

LobbyistCovered position, as disclosed
JEREMY ALLEN —
EUSTACIA LEE REIDY —
AMIT K SACHDEV —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2552 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.